Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer

摘要: Background. No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy. In vitro data suggest that FU resistance can be overcome by continuous infusion (CI) FU, the cytotoxic effects of Mitomycin-C (MMC) are synergistic. Based on this data, a Phase II trial CI LV MMC in carcinoma progressed only one previous chemotherapy regimen was performed. Methods. Twenty-eight had FU/LV were treated 10 mg/m2 every 6 weeks 200 mg/m2/day admixed given 14 days on/7 off. Results. The partial response rate 24 evaluable 17% (95% confidence interval, 2-32%) median duration 9.5 months (range, 4.2-12.0 months). Twelve (50%) additional achieved disease stabilization. Median survival 9.9 whole group (28 patients) 11.5 patients. major toxicities grade 4 diarrhea occurring two 3 mucositis five There minimal myelosuppression (grade thrombocytopenia patient) no occurrences hand-foot syndrome or cardiotoxicity. Conclusions. This demonstrates modest activity acceptable toxicity have failed single-bolus regimen. Modifications other infusional FU-based regimens should explored as potential cancer. Cancer 1995;75:769-74.